Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.24.1.1.u2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Apr. 30, 2024
Apr. 30, 2023
Apr. 30, 2024
Apr. 30, 2023
Income Statement [Abstract]        
Revenue $ 210 $ 210
Operating costs and expenses:        
Inventor royalties, contingent legal fees, litigation and licensing expenses 161 161
Research and development expenses (including non-cash stock-based compensation expenses of $520, $492, $1,009 and $998, respectively) 1,646 998 2,995 2,066
General and administrative expenses (including non-cash stock-based compensation expenses of $740, $735, $1,511 and $1,292, respectively) 1,821 1,611 4,081 3,099
Total operating costs and expenses 3,467 2,770 7,076 5,326
Loss from operations (3,467) (2,560) (7,076) (5,116)
Interest income 287 253 606 455
Net loss (3,180) (2,307) (6,470) (4,661)
Less: Net loss attributable to noncontrolling interest (41) (19) (76) (51)
Net loss attributable to common shareholders $ (3,139) $ (2,288) $ (6,394) $ (4,610)
Net loss per common share attributable to common shareholders:        
Basic $ (0.10) $ (0.07) $ (0.20) $ (0.15)
Diluted $ (0.10) $ (0.07) $ (0.20) $ (0.15)
Weighted average common shares outstanding:        
Basic 31,914 30,930 31,677 30,924
Diluted 31,914 30,930 31,677 30,924